Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of SNIPR Biome.

    Client Virtual Booth

    SNIPR BIOME

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    SNIPR Biome
    Denmark Flag
    Country
    Country
    Denmark
    Address
    Address
    Lersø Parkallé 44 2100 Copenhagen
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sniprbiome.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/sniprbiome/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SNIPR Biome Reports Positive Clinical Interim Results for Groundbreaking, First-in-Human, CRISPR-based Microbial Gene Therapy

    Details:

    SNIPR001 is a novel, first-in-human, CRISPR-based microbial gene therapy, developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract.


    Lead Product(s): SNIPR001

    Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

    Highest Development Status: Phase IProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 31, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SNIPR Biome Further Strengthens CRISPR/Cas IP Portfolio With Patent Grant

    Details:

    SNIPR’s CRISPR technology provides a highly selective way to target individual bacterial strains for killing which can be useful for the prevention and treatment of any indication where a specific bacterial strain is the underlying cause of a disease.


    Lead Product(s): SNIPR001

    Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

    Highest Development Status: Phase IProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 22, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryotes

    Details:

    SNIPR001, is the first orally dosed CRISPR-based therapeutic candidate and CRISPR-armed bacteriophage cocktail that targets antibiotic-resistant E. coli infections in hematological cancer patients.


    Lead Product(s): SNIPR001

    Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

    Highest Development Status: Phase IProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 03, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phage

    Details:

    SNIPR001, a CRISPR-armed bacteriophage cocktail that targets the prevention of antibiotic-resistant E. coli infections in hematological cancer patients.


    Lead Product(s): SNIPR001

    Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

    Highest Development Status: Phase IProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 02, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001

    Details:

    The experimental CRISPR therapeutic, SNIPR001, is designed to selectively target and eradicate E. coli in the gut, thus preventing translocation of these bacteria to the bloodstream, in a high-risk population of hematological cancer patients at risk for neutropenia.


    Lead Product(s): SNIPR001

    Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

    Highest Development Status: Phase IProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 20, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. col...

    Details:

    INDA approval is based on the positive pre-clinical data for SNIPR001 which showed that it holds a huge potential against life-threatening infections and also in modulating microbiome-associated diseases.


    Lead Product(s): SNIPR001

    Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

    Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 11, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search